The usefulness of serum beta-2 microglobulin as a biomarker for evaluating renal function decline in type II diabetes mellitus

Zainab A. Hussein1,2, Sura A. Abdulsattar1 and Issam N. Salman3

1Department of Chemistry and Biochemistry, College of Medicine, Mustansiriyah University, Baghdad, Iraq
2Department of Medical Laboratory Techniques, Al-Farabi University College, Baghdad, Iraq
3National Diabetes Center for Research and Treatment, Mustansiriyah University, Baghdad, Iraq

ABSTRACT

Background and objective: Serum beta-2 microglobulin (β2M) has been used as a useful clinical marker of chronic kidney dysfunction. The current study aims to evaluate the diagnostic accuracy of β2M for the early detection of diabetic nephropathy among Iraqi patients with type II diabetes mellitus.

Methods: The study included 84 participants divided into four groups, three of them were type II diabetics and the fourth is the healthy individuals' (control) group. The diabetic' subgroups were named according to the Micral test as: normoalbuminuria (21 patients), microalbuminuria (21 patients), and macroalbuminuria group (21 patients). The control group included 21, age- and sex-matched, healthy participants. Biochemical markers for diabetes mellitus as well as β2M were determined for each participant and then were analyzed statistically.

Results: The serum β2M of normoalbuminuria group was (2.86 ± 0.95 g/mL), microalbuminuria group was (5.06 ± 1.97 g/mL) and macroalbuminuria group (3.6 ± 1.59 g/mL). The results showed significant increase (p < 0.05) in the β2M level of microalbuminuria group when compared with that of normoalbuminuria and macroalbuminuria groups. In addition, a highly significant increase (p < 0.01) in β2M concentration was observed in microalbuminuria group when compared with that of the control group.

Conclusions: β2M can be used as a useful biomarker for the early detection of diabetic nephropathy.

Keywords beta-2 microglobulin, diabetic nephropathy, diabetes mellitus, macroalbuminuria

INTRODUCTION

Beta-2 microglobulin (β2M) is a protein (11,800 Dalton) found in almost all nucleated cells and most body fluids, including serum, urine, and synovial fluid. In humans, it is
encoded by the $B2M$ gene that located on the chromosome 15 and consists of 99 amino acids with one disulfide bond.\textsuperscript{1,2} The abnormal level of $\beta2M$ in blood or urine is mostly associated with certain diseases, such as some acute and chronic inflammations, liver or renal dysfunctions, some viral infections, and several malignancies.\textsuperscript{3} The serum $\beta2M$ level is inversely correlated with the glomerular filtration rate (GFR), as one of the classic low-molecular-weight indicators of kidney function.\textsuperscript{4} At the same time, several non-renal factors, such as systolic blood pressure, gender, total cholesterol, inflammation, and smoking have an effect on serum $\beta2M$ concentration.\textsuperscript{5} About 99\% of $\beta2M$ is eliminated by glomerular filtration and mostly it reabsorbed by the proximal tubules and less than 1\% of the filtered amount is excreted in the urine.\textsuperscript{6} Thus, in individuals with chronic kidney disease and especially end-stage renal disease, $\beta2M$ is increased in the blood.\textsuperscript{7} In addition, its levels were significantly and positively correlated with the end stage renal disease.\textsuperscript{8} In general, the plasma $\beta2M$ elevation is mostly resultant from the decreased glomerular filtration rate or increased rate of its synthesis.\textsuperscript{9}

The $\beta2M$ is the most efficient test for the detection of proximal tubular dysfunction. However, urinary $\beta2M$ determination is important for following-up renal transplantation patients.\textsuperscript{10} Renal filtration and reabsorption disorders can be detected by abnormal urinary $\beta2M$ values. Because of its small size, $\beta2M$ passes through the glomerular membrane and reabsorbed by specific receptors in the proximal tubules. Its concentrations increase due to the decreased ability to reabsorb this protein. When the glomeruli are damaged, they become unable to filter out $\beta2M$, and this leads to elevated blood concentration, while tubular injury leads to decreased reabsorption of $\beta2M$, leading to elevated urinary concentrations.\textsuperscript{11} Till now, there is no research study showing the role of serum $\beta2M$ as a clinical predictor for kidney dysfunction in Iraqi patients with type II diabetes mellitus. Thus, the current study was designed to investigate the diagnostic accuracy of $\beta2M$ for the early detection of diabetic nephropathy among Iraqi patients with type II diabetes mellitus.

**MATERIALS AND METHODS**

**Study design and subjects**

This case-control study was conducted at the National Diabetes Center for Treatment and Research of Mustansiriyah University (Baghdad, Iraq). Eighty-four participants included in the study and divided into four groups, three of which included type II diabetes mellitus patients diagnosed depending on the case history, levels of fasting blood sugar (FBS) and HbA$_1$c. They were divided, according to the Micral test (urine albumin/creatinine ratio), into three groups classified as: normalalbuminuria (21 participants), 21 microalbumuninuria (21 participants), and 21 macroalbumininuria (21 participants). The fourth group included 21 apparently healthy subjects, in term of non-diabetes, with matched gender and age. Patients with type 1 diabetes, gestational diabetes, chronic disease, cardiovascular and other complications of diabetes mellitus, patients on insulin therapy, smoker patients were excluded.
Ten milliliters of fasting blood taken from each participant. Four milliliters were placed in EDTA tube for the measurement of glycated hemoglobin (HbA1c). The remaining 6 milliliters of blood were placed into gel-containing anticoagulant-free tubes and allowed to clot at room temperature for 2 hours to be analyzed later. The urine sample of each participant was also collected for the Micral test.

**Biochemical parameters**

Serum β2M and insulin were determined quantitatively by the enzyme-linked immunosorbent assay (ELISA) in vitro, using commercial kits ELISA manufactured by Demeditec, Germany. The renal profile, blood sugar and HbA1c were assessed by using cobas c311 (Roche, Germany). Insulin resistance was measured by HOMA-IR while beta cell function estimated by HOMA-β as shown in the following equations:

\[
HOMA-IR = \frac{(FBS_{(mmol/L)} \times FI_{(\muIU/mL)})}{22.5}
\]

\[
HOMA-\beta = \left( \frac{20 \times FI_{(\muIU/mL)}}{FBS_{(mmol/L)} - 3.3} \right) \%
\]

**Statistical analysis**

Statistical Package for Social Sciences, SPSS v19 (IBM, IL, USA) was used for data analysis. The quantitative variables (measured parameters) were expressed as means±standard deviation (SD) by using analysis of variation (ANOVA) to compare between means, a p-value of ≤0.05 was considered statistically significant. In addition, receiver operating characteristics (ROC) curve was used to evaluate the marker accuracy as predictor. The best cut-off point of β2M, sensitivity, and specificity were also calculated.

**RESULTS**

The results of age and BMI presented in Table 1 showed no significant differences (p>0.05) between studied groups. The mean value of age were 54.59 years, 56.52 years, 58.4 year and 54.5 years for control, normoaluminuria, microaluminuria, and macroalbuminuria, respectively. The BMI results of all groups indicated that all participants were obese (BMI>30 kg/m²).

The mean±SD of serum β2M of normoalbuminuria group was (2.86±0.95 µg/mL), microalbuminuria group was (5.06±1.97 µg/mL) and macroalbuminuria group (3.6±1.59 µg/mL). The comparison results indicated significant increase (p<0.05) of β2M in microalbuminuria group in comparison to that of normoalbuminuria and macroalbuminuria groups. Also, highly significant increase of β2M was observed in microalbuminuria group
in comparison to that of control group. The profile of blood sugar for studied groups indicated highly significant differences \((p<0.01)\) in FBG, insulin, HbA1c, HOMA-IR, and HOMA-\(\beta\) between all studied groups as shown in Table 1. Meanwhile, the renal function tests for studied groups revealed highly significant differences \((p<0.01)\) in serum urea, creatinine, GFR, and albumin/creatinine ratio of urine between all studied groups as shown in Table 1.

| Parameter      | Group I     | Group II    | Group III   | Group IV    | \(P\)  |
|----------------|-------------|-------------|-------------|-------------|-------|
| Age (years)    | 54.59±9.71  | 56.52±8.12  | 58.47±9.97  | 54.50±9.75  | 0.52  |
| BMI (Kg/m\(^2\)) | 30.57±3.76  | 32.19±5.45  | 31.60±3.44  | 30.88±4.53  | 0.80  |
| FBG (mg/dL)    | 90.17±9.67  | 162.52±71.21| 194.26±48.01| 211.53±79.2 | 0.001 |
| FPI (U/mL)     | 12.65±2.77  | 9.65±2.44   | 11.98±3.43  | 15.76±6.01  | 0.02  |
| HbA1c (%)      | 5.54±0.21   | 8.44±1.97   | 8.81±1.42   | 9.56±1.88   | 0.001 |
| HOMA-IR        | 50.88±18.01 | 70.55±26.10 | 112.64±27.63| 178.59±77.99| 0.001 |
| HOMA-\(\beta\) (%) | 2.55±0.87   | 1.38±0.32   | 1.49±0.496  | 1.54±0.62   | 0.001 |
| B. urea (mg/dL)| 23.85±5.37  | 25.35±6.56  | 28.32±9.33  | 40.94±5.04  | 0.001 |
| S. creatinine (mg/dL) | 0.57±0.10   | 0.68±0.19   | 0.83±0.24   | 1.52±0.37   | 0.001 |
| GFR (mL/min/1.73 m\(^2\)) | 117.39±25.7 | 107.41±31.35| 84.71±26.41 | 45.16±13.43 | 0.001 |
| A/C ratio (mg/mmol) | 1.38±0.41   | 1.95±1.08   | 10.28±5.21  | 32.3±8.87   | 0.001 |
| \(\beta\)2M (\(\mu\)g/mL) | 2.35±0.56   | 2.86±0.95   | 5.06±1.97   | 3.6±1.59    | 0.001 |

Group I (control), Group II (DM patients with normoalbuminuria), Group III (DM patients with microalbuminuria), Group IV (DM patients with macroalbuminuria).

**A/C ratio**, albumin:creatinine ratio; **BMI**, body mass index; **FBG**, fasting blood sugar or glucose; **GFR**, glomerular filtration rate; **FPI**, fasting plasma insulin; **\(\beta\)2M**, beta-2 microglobulin.

As shown in Table 2, the Pearson correlation analysis of \(\beta\)2M results showed highly significant positive correlation \((p<0.01)\) between \(\beta\)2M and HOMA-\(\beta\), urea, and (A/C ratio) in normoalbuminuria group. Macroalbuminuria group showed highly significant \((p<0.01)\) positive correlation with HOMA-IR, urea and creatinine, meanwhile indicate a highly significant \((p<0.01)\) negative correlation with GFR (Table 2). The results of \(\beta\)2M of macroalbuminuria group showed a highly significant \((p<0.01)\) positive correlation with urea and creatinine, while a highly significant \((p<0.01)\) negative correlation with GFR was observed (Table 2).

Receiver operating characteristics (ROC) curve was used to evaluate the usefulness of \(\beta\)2M in optimal diagnosis of diabetic nephropathy. In normoalbuminuria group, as in Table 3, the area under curve (AUC) was 0.7, sensitivity 65.2%, and specificity 63.6%. In addition, the AUC in microalbuminuria group was 0.98, sensitivity 90.5%, and specificity 90.9%. Meanwhile, in macroalbuminuria group, the AUC was 0.74, sensitivity 68.2%, and specificity 68.2%.

**DISCUSSION**
The β2M is located on the surface of lymphocytes and other nucleated cells. The free molecules are also detectable in plasma as products of circulating cells, particularly from lymphocytes. Since the kidneys are the primary site of clearance, the serum β2M is highly dependent on renal function. As a result, the β2M has been used as a nephropathies biomarker.\(^\text{13}\)

In the current study, the result of β2M level in sera of nephropathy patients indicated significant increase compared to that of control group. This was in agreement with Herrero-Morin et al study, in 2007,\(^\text{14}\) which reported that β2M is wholly filtered at the glomerulus and then almost completely reabsorbed in the proximal tubule. In healthy conditions its production is constant, thus making it suitable as a replacement for GFR.\(^\text{12}\)

Meanwhile, a study by Sedighi O and his colleagues\(^\text{15}\) found that plasma β2M levels were higher in patients with CKD, and that this level increased as GFR decreased. Since β2M is removed by glomerular filtration and tubular catabolism in the kidneys, its plasma level is closely linked to GFR.\(^\text{7}\)

Colombo et al (2019) have shown that β2M can be used as a biomarker of renal function decline from an eGFR of 30-75 ml.min\(^{-1}\) [1.73 m\(^2\)] in type 2 diabetes.\(^\text{16}\) The β2M freely

---

**Table 2** Pearson correlation analysis between β2M and other studied variables.

| Variable       | Group II |            | Group III |            | Group IV |            |
|----------------|----------|------------|-----------|------------|----------|------------|
| Age (years)    | r        | 0.29       | p         | 0.16       | r        | 0.30       | p         | 0.18       | r        | 0.19       | p         | 0.38       |
| BMI (Kg/m\(^2\)) |          | -0.13      |            | 0.54       | -0.13    | 0.30       |            | 0.18       | -0.13    | 0.90       |            | 0.55       |
| FBG (mg/dL)    |          | -0.24      |            | 0.26       | -0.24    | -0.02      |            | 0.90       | -0.02    | 0.97       |            | 0.86       |
| FPI (U/mL)     |          | 0.15       |            | 0.47       | 0.15     | -0.21      |            | 0.35       | -0.21    | 0.35       |            | 0.68       |
| HbA1c (%)      |          | -0.40      |            | 0.08       | -0.40    | 0.12       |            | 0.60       | 0.12     | 0.60       |            | 0.65       |
| HOMA-IR        |          | -0.11      |            | 0.63       | -0.11    | 0.71       |            | 0.001      | 0.71     | 0.001      |            | 0.82       |
| HOMA-β (%)     |          | 0.46       |            | 0.03       | 0.46     | 0.23       |            | 0.31       | 0.23     | 0.31       |            | 0.64       |
| B. urea (mg/dL)|          | 0.22       |            | 0.001      | 0.22     | 0.24       |            | 0.001      | 0.24     | 0.001      |            | 0.35       |
| S. creatinine (mg/dL) |      | 0.00       |            | 0.58       | 0.00     | 0.44       |            | 0.001      | 0.44     | 0.001      |            | 0.27       |
| GFR (mL/min/1.73 m\(^2\)) |   | -0.01      |            | 0.43       | -0.01    | -0.48      |            | 0.001      | -0.48    | 0.001      |            | -0.22      |
| A/C ratio (mg/mmol) |  | 0.56       |            | 0.001      | 0.56     | -0.08      |            | 0.72       | -0.08    | 0.72       |            | 0.10       |

**Table 3** Receiver operating characteristics (ROC) curve analysis of β2M.

|                  | Group II |            | Group III |            | Group IV |            |
|------------------|----------|------------|-----------|------------|----------|------------|
| AUC              |          | 0.70       |            | 0.98       |          | 0.74       |
| Cut-off level (μg/mL) |     | 2.61       |            | 3.44       |          | 2.72       |
| Sensitivity (%)  |          | 65.2       |            | 90.5       |          | 68.2       |
| Specificity (%)  |          | 63.6       |            | 90.9       |          | 68.2       |
passes through the glomerular filtration membrane, where it is absorbed and degraded almost entirely by the proximal tubules, without being secreted and returned to the blood.\textsuperscript{16} Although only small amount of $\beta 2M$ might be filtered by the glomeruli, the majority are catabolized in the tubules, however; all these notes make it a good marker for kidney disease.\textsuperscript{17}

In Indian patients with type II diabetes mellitus, the study was demonstrated higher association between $\beta 2M$ and increased risk of incident end-stage renal disease (ESRD), and thus $\beta 2M$ is associated with mortality in Indian patient with type II diabetes mellitus.\textsuperscript{18} Kim \textit{et al}\textsuperscript{19} and Cheung \textit{et al}\textsuperscript{20} studies found that the patients with high levels of $\beta 2M$ had higher prevalence of diabetic nephropathy and retinopathy than those with low $\beta 2M$ levels. In general, the effect of $\beta 2M$ is slightly higher on diabetes mortality than all other causes of mortality because its high levels were found to be associated with multiple diabetic complications.\textsuperscript{19,20} In the present study, the $\beta 2M$ level was significantly correlated with all markers of kidney function (serum urea and creatinine). Patients with significantly higher $\beta 2M$ levels were more frequently seen in the microalbuminuria group compared to those with macroalbuminuria, which might reflect the renal treatment effects on $\beta 2M$ levels. Also, according to ROC curve analysis which indicted that $\beta 2M$ levels of type II diabetes mellitus with normoalbuminuria, greater than or equal to $2.61 (\mu g/mL)$ with 63.60% specificity and 65.20% sensitivity and the (AUC=0.70, $p=0.02$) that mean $\beta 2M$ is fair marker for predicting nephropathy in type 2 diabetics. While, $\beta 2M$ of type II diabetics in microalbuminuria group greater than or equal to 3.44 $(\mu g/mL)$ with 90.90% specificity and 90.50% sensitivity and the (AUC=0.98, $p=0.001$ that serum mean $\beta 2M$ is prefect marker for predicting nephropathy in type 2 diabetes mellits. Meanwhile, $\beta 2M$ levels of type II diabetes mellitus in macroalbuminuria group greater than or equal to 2.72 $(\mu g/mL)$ with 68.20% specificity and 68.20% sensitivity and the (AUC=0.74, $p=0.006$) that mean $\beta 2M$ is fair for predicting nephropathy in type II diabetes mellitus, and to confirm that our results more studies are needs.

CONCLUSIONS

Signs of renal damage appeared to be parallel to diabetic nephropathy and assessed by reduced glomerular filtration rate, and it is possible to use $\beta 2M$ as a predictive marker rather than prognostic marker for diabetic nephropathy.

ABBREVIATIONS

$\beta 2M$, Beta-2-Microglobulin; BMI, Body Mass Index; FBS, Fasting Blood Sugar; GFR, Glomerular Filtration Rate HbA$_{1c}$, Hemoglobin A$_{1c}$; HOMA-IR, Homeostatic Model Assessment of Insulin Resistance; INS, Insulin; ROC, Receiver Operator Characteristics.
ACKNOWLEDGMENTS

The authors are grateful to all patients who participated in this study.

DECLARATIONS

Authors’ contributions

SAA conceived the presented idea and wrote the manuscript. ZAH carried out the experiment and verified the analytical methods with support from SAA. INS developed the theory and performed the computations. All authors discussed the results, reviewed and approved the final manuscript.

Conflict of interest

The authors have no conflict of interest.

Ethical approvals

This study was approved by the Scientific Committee of Chemistry and Biochemistry Department, College of Medicine at University of Mustansiriyah, and by the scientific Committee of the National Diabetes Center (Ref. No.: 4786/9.11.2019). The objectives and methodology were explained to all participants and verbal consent had been taken.

Data availability

The data that support the findings of this study is available from the corresponding author, upon reasonable request.

Funding resources

No external fund was received.

REFERENCES

1. Becker JW, Reeke GN. Three-dimensional structure of beta 2-microglobulin. Proc Natl Acad Sci. 1985;82(12):4225–4229. Available from: 10.1073/pnas.82.12.4225.
2. Li L, Dong M, Wang XG. The implication and significance of beta 2 microglobulin: a conservative multifunctional regulator. Chin Med J (Engl). 2016;129(4):448–455. Available from: 10.4103/0366-6999.176084.
3. Drüeke TB, Massy ZA. Progress in uremic toxin research: beta2-microglobulin. Seminars in Dialysis. 2009;22:378–380. Available from: 10.1111/j.1525-139X.2009.00584.x.
4. Behairy OG, Almonaem A, Abed ER, T N. Role of serum cystatin-C and beta-2 microglobulin as early markers of renal dysfunction in children with beta thalassemia major. Int J Nephrol Renovasc Dis. 2017;10:261–268. Available from: 10.2147/IJNRD.S142824.
5. Stanga Z, Nock S, Medina-Escobar P, Nydegger UE, Risch M, Risch L. Factors other than the glomerular filtration rate that determine the serum beta-2-microglobulin level. PLoS One. 2013;8(8):e72073–e72073. Available from: 10.1371/journal.pone. 0072073.

6. Argyropoulos CP, Chen SS, Ng YH, et al. Rediscovering beta-2 microglobulin as a biomarker across the spectrum of kidney diseases. Front Med (Lausanne). 2017;4:73–73. Available from: 10.3389/fmed.2017.00073.

7. Estakhri A, Kavakeb M, Fathi P, Karimi D, Mohammadpour G, Rahbar A, et al. An investigation of the relationship between beta-2 microglobulin (β2M) and inflammatory factors (serum levels of CRP and albumin) and high density lipoproteins (HDL) in hemodialysis patients. Mod Med Lab J. 2017;1(1):17–22. Available from: 10.30699/mmlj17-01-04.

8. Topçiu-Shufta V, Miftari R, Haxhibeqiri V, Haxhibeqiri S. Association of beta-2 microglobulin with inflammation and dyslipidemia in high-flux membrane hemodialysis patients. Med Arch. 2016;70(5):348–350. Available from: 10.5455/medarch.2016.70.348-350.

9. Karlsson FA, Wibell L, Ehrin PE. beta 2-Microglobulin in clinical medicine. Scand J Clin Lab Invest Suppl. 1980;154:27–37.

10. Light JA, Biggers JA, Alijani MR, Smith M, Oddendino K. Serum beta-2-microglobulin: an adjunctive monitoring test in renal transplantation. Proc Clin Dial Transplant Forum. 1980;10:67–73.

11. Puthiyottil D, Priyamvada PS, Kumar MN, Chellappan A, Zachariah B, Parameswaran S. Role of urinary beta 2 microglobulin and kidney injury molecule-1 in predicting kidney function at one year following acute kidney injury. Int J Nephrol Renovasc Dis. 2021;14:225–234. Available from: 10.2147/IJNRD.S319933.

12. Jensen JE, Nielsen SH, Foged L, Holmegaard SN, Magid E. The MICRAL test for diabetic microalbuminuria: predictive values as a function of prevalence. Scand J Clin Lab Invest. 1996;56(2):117–122. Available from: 10.3109/00365519609088597.

13. Puthiyottil D, Priyamvada PS, Kumar MN, Chellappan A, Zachariah B, Parameswaran S. Role of Urinary Beta 2 Microglobulin and Kidney Injury Molecule-1 in Predicting Kidney Function at One Year Following Acute Kidney Injury. Int J Nephrol Renovasc Dis. 2021;14:225–234. Available from: 10.2147/IJNRD.S319933.

14. Herrero-Morín JD, Málaga S, Fernández N. Cystatin C and beta2-microglobulin: markers of glomerular filtration in critically ill children. Crit Care. 2007;11:59–59. Available from: 10.1186/cc5923.

15. Sedighi O, Abediankenari S, Omranifar B. Association between plasma Beta-2 microglobulin level and cardiac performance in patients with chronic kidney disease. Nephrourol Mon. 2014;7(1). Available from: 10.5812/nemonthly.23563.

16. Colombo M, Looker HC, Farran B. Serum kidney injury molecule 1 and β2-microglobulin perform as well as larger biomarker panels for prediction of rapid decline in renal function in type 2 diabetes. Diabetologia. 2019;62(1):156–168. Avail-
able from: 10.1007/s00125-018-4741-9.

17. Lu HY, Ning XY, Chen YQ. Predictive Value of Serum Creatinine, Blood Urea Nitrogen, Uric Acid, and β2-Microglobulin in the Evaluation of Acute Kidney Injury after Orthotopic Liver Transplantation. Chin Med J (Engl). 2018;131(9):1059–1066.

18. Foster MC, Inker LA, Hsu CY. Filtration markers as predictors of ESRD and mortality in Southwestern American Indians with type 2 diabetes. Am J Kidney Dis. 2015;66(1):75–83. Available from: 10.1053/j.ajkd.2015.01.013.

19. Kim MK, Yun KJ, Chun HJ. Clinical utility of serum beta-2-microglobulin as a predictor of diabetic complications in patients with type 2 diabetes without renal impairment. Diabetes Metab. 2014;40(6):459–465. Available from: 10.1016/j.diabet.2014.08.002.

20. Cheung CL, Lam KS, Cheung BM. Serum β-2 microglobulin predicts mortality in people with diabetes. Eur J Endocrinol. 2013;169(1):1–7. Available from: 10.1530/EJE-13-0003.

**AUTHOR BIOGRAPHY**

**Zainab A. Hussein** is currently working as an assistant lecturer (M.Sc.) of clinical biochemistry at the Department of Medical Laboratory Techniques, Al-Farabi University College (Baghdad, Iraq).

**Sura A. Abdulsattar** is a professor (with a Ph.D.) of Biochemistry at the Department of Chemistry and Biochemistry, College of Medicine, Mustansiriyah University (Baghdad, Iraq).

**Issam N. Salman** is an assistant professor (with a Ph.D. in Internal Medicine) of Diabetes and Endocrinology at the National Diabetes Center, Mustansiriyah University (Baghdad, Iraq).